|

BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Liposomal Bcl-2; L-Bcl-2

Pipeline

Phase 1: 1

Top Sponsors

  • Bio-Path Holdings, Inc.1

Indications

  • Acute Myeloid Leukemia, in Relapse1
  • Acute Myeloid Leukemia Refractory1
  • Cancer1

La Jolla, California1 trial

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Scripps Green Hospital

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.